期刊
INTERNATIONAL JOURNAL OF CANCER
卷 152, 期 5, 页码 977-985出版社
WILEY
DOI: 10.1002/ijc.34323
关键词
acute lymphoblastic leukemia; haploidentical hematopoietic stem cell transplantation; TP53 mutation
类别
Previous studies have shown that TP53 mutation is associated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). However, a new study suggests that TP53 mutation may not impact survival in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
Previous studies have demonstrated that TP53 mutation is correlated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). Few studies have investigated the impact of TP53 mutation in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT). We completed a retrospective study of 65 ALL patients with available TP53 status who underwent haplo-HSCT. They were divided into a TP53 mutation group (TP53(mut)) and a TP53 wild-type (TP53(wt)) group. TP53(mut) showed comparable 2-year cumulative incidence of relapse (CIR) rates (13.1% vs 12.5%, P = .96) and 2-year leukemia-free survival (LFS) (74.2% vs 77.4%, P = .80) with TP53(wt). No significant differences in 2-year overall survival (OS) rates (82.9% vs 87.3%, P = .61) or 2-year NRM rates (12.7% vs 10.2%, P = .69) were observed in TP53(mut) and TP53(wt) patients. Multivariate analysis suggested that white blood cell (WBC) count at initial diagnosis (>50 x 10(9)/L: hazard ratio [HR] = 3.860, P = .016) and age (>40 years old: HR = 4.120, P = .012) are independent risk factors for 2-year LFS. Our study showed that TP53 mutations may not be related to the unfavorable impact on survival in ALL patients after treatment with haplo-HSCT. The present results suggested that haplo-HSCT may eliminate the poor prognosis effect of TP53 mutation in ALL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据